Laboratory findings
| . | Standard-risk patients (n = 114) . | |
|---|---|---|
| . | Median . | Range . |
| Hemoglobin, g/dL | 10.2 | 2.1-34 |
| Peripheral WBC count, ×103/µL | 5.5 | 1.4-103.4 |
| Peripheral platelet count, ×103/µL | 40.5 | 3-339 |
| Peripheral blasts, % | 3 | 0-88.9 |
| Bone marrow blast, % | 22 | 0-100 |
| Cytogenetic findings (n = 110 patients) | N | % |
| Normal (constitutional trisomy 21 only) | 19 | 17 |
| Translocations and inversions recurrent in de novo AML | 0 | 0 |
| 1q gain | 12 | 11 |
| 3q loss | 6 | 5 |
| 5p loss | 5 | 5 |
| Monosomy 5 | 1 | 1 |
| 7p loss | 14 | 13 |
| Monosomy 7 | 7 | 6 |
| +8 | 33 | 30 |
| +11 or 11q gain | 8 | 7 |
| 13q loss | 5 | 5 |
| +14 | 8 | 7 |
| +21 | 18 | 16 |
| Complex karyotype | 13 | 12 |
| . | Standard-risk patients (n = 114) . | |
|---|---|---|
| . | Median . | Range . |
| Hemoglobin, g/dL | 10.2 | 2.1-34 |
| Peripheral WBC count, ×103/µL | 5.5 | 1.4-103.4 |
| Peripheral platelet count, ×103/µL | 40.5 | 3-339 |
| Peripheral blasts, % | 3 | 0-88.9 |
| Bone marrow blast, % | 22 | 0-100 |
| Cytogenetic findings (n = 110 patients) | N | % |
| Normal (constitutional trisomy 21 only) | 19 | 17 |
| Translocations and inversions recurrent in de novo AML | 0 | 0 |
| 1q gain | 12 | 11 |
| 3q loss | 6 | 5 |
| 5p loss | 5 | 5 |
| Monosomy 5 | 1 | 1 |
| 7p loss | 14 | 13 |
| Monosomy 7 | 7 | 6 |
| +8 | 33 | 30 |
| +11 or 11q gain | 8 | 7 |
| 13q loss | 5 | 5 |
| +14 | 8 | 7 |
| +21 | 18 | 16 |
| Complex karyotype | 13 | 12 |